Role of Ο6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 735-741

  Bobola, Michael S ^a,b   Tseng, Sheng Hong ^c   Blank, A ^a   Berger, Mitchel S ^a,b   Silber, John R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

0 6 METHYLGUANINE DNA METHYL TRANSFERASE; MESYLIC ACID METHYL ESTER; STREPTOZOCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; GUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLNITRONITROSOGUANIDINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE; CELL CULTURE; DRUG RESISTANCE; METHYLATION; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GUANINE; HUMANS; METHYL METHANESULFONATE; METHYLATION; METHYLNITRONITROSOGUANIDINE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; STREPTOZOCIN; TUMOR CELLS, CULTURED;

EID: 0029657595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. 6-methylguanine-DNA methyltransferase to monofunctional alkylating agent resistance in human brain tumor-derived cell lines. Mol. Carcinog., 13: 70-80, 1995.
2. 6-methylguanine-DNA methyltransferase to resistance to 1,3-bis(2-chloroethyl)-l-nitrosourea in human brain tumor-derived cell lines. Mol. Carcinog., 13: 81-88, 1995.
3. 6-methylguanine-DNA methyltranferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol. Carcinog., 4: 482-488, 1991.
4. 6-methylguanine-DNA methyltranferase in excision repair-deficient Chinese hamster ovary cells and its response to certain alkylating agents. Cancer Res., 52: 32-35, 1992.
5. Hata, H., Numata, M., Tohda, H., Yasui, A., and Oikawa, A. Isolation of two chloroethylnitrosourea-sensitive Chinese hamster ovary cell lines. Cancer Res., 51: 195-198, 1991.
6. Matijasevic, Z., Boosalis, M., McKay, W., Samson, L., and Ludlum, D. B. Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase. Proc. Natl. Acad. Sci. USA, 90: 11855-11859, 1993.
7. Bodell, W. J., Tokuda, K., and Ludlum, D. B. Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitosourea. Cancer Res., 48: 4489-4492, 1988.
8. Matijasevic, Z., Bodell, W J., and Ludlum, D. B. 3-Methyladenine DNA glycosylase activity in a glial cell line sensitive to the haloethylnitrosoureas in comparison with a resistant line. Cancer Res., 51: 1568-1570, 1991.
9. Seidenfeld, J., and Sprague, W. S. Comparisons between sensitive and resistant tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy. Cancer Res., 50: 521-526, 1990.
10. Ferguson, L. R. Mutagenic and recombinogenic consequences of DNA repair inhibition during treatment with 1,3-bis(2-chloroethyl)-l-nitrosourea in Sacharomyces cerevisiae. Mutat. Res., 241: 369-377, 1990.
11. Kacinski, B. M., Rupp, W. D., and Ludlum, D. B. Repair of haloethylnitrosourea-induced DNA damage in mutant and adapted bacteria. Cancer Res., 45: 6471-6474, 1985.
12. Colvin, M. The alkylating agents. In: Chabner, B. (ed.), Pharmacological Principles of Cancer Treatment, pp. 276-308. Philadelphia: W. B. Saunders Co., 1985.
13. Weinkam, R. J., Shiba, D. A., and Chabner, B A. Nonclassical alkylating agents. In: Chabner, B. (ed.), Pharmacological Principles of Cancer Treatment, pp. 340-362. Philadelphia: W. B. Saunders Co., 1985.
14. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hoffman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br. J. Cancer, 65: 287-291, 1992.
15. Berger, M. S., Spence, A. M., and Stelzer, K. J. Brain tumors. In: Brain, M. C., and Carbone, P. P. (eds.), Current Therapy in Hematology/ Oncology, pp. 525-542. Philadelphia: Mosby Publishers, Inc., 1995.
16. Stewart, D. J. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev., 16: 129-160, 1989.
17. Levin, V. A., and Prados, M. D. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J. Clin. Oncol., 10: 766-777, 1992.
18. Levin, V. A., Silver, P., Hannigan, X. X., Wara, W. M., Gutin, P. H., Davis, R. L., and Wilson, C. B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radat. Oncol. Biol. Phys., 18: 321-324, 1990.
19. Rodriguez, L. A., Prados, M., Silver, P., and Levin, V. A. Reevaluation of procarbazine for treatment of recurrent malignant central nervous system tumors. Cancer (Phila.), 64: 2420-2423, 1989.
20. Newton, H. B., Junck, L., Bromberg, J., Page, M. A., and Greenberg, H. S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology, 40: 1743-1746, 1990.
21. Rostomily, R. C., Spence, A. M., Duong, D., McCormick, K., Bland, M., and Berger, M. S. Multimodality management of recurrent adult malignant gliomas: results of a Phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery (Baltimore), 35: 378-388, 1994.
22. O'Reilly, S. M., Newlands, E. S., Glaser, M. G., Brampton, B., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun. I. R., Lewis, P., and Stevens, M. F. G. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur. J. Cancer. 29A: 940-942, 1993.
23. Singer, B., and Grunberger, D. Molecular Biology of Mutagens and Carcinogens. New York: Plenum Publishing Corp., 1983.
24. Saffhill, R., Margison, G. P., and O'Conner, P. J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim. Biophys. Acta. 823: 111-145, 1985.
25. Beranek, D. T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res., 231: 11-30, 1990.
26. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res., 51: 167-223, 1995.
27. Karran, P., and Bignami, M. DNA damage tolerance, mismatch repair and genomic instability. BioEssays, 16: 833-839, 1994.
28. 6-benzylguannie analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
29. 6-benzylguanine and ethacrynic acid in haematological malignancies. Anticancer Res., 13: 2155-2160, 1993.
30. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br. J. Cancer. 67: 1299-1302, 1993.
31. Friedman, H. S., Dolan, M. E., Pegg, A E., Marcelli, S., Keir, S., Catino, J. J., Bigner, D. D., and Schold, S. C. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
32. 6-methylguanine-DNA methyltranferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis (Lond.), 12: 1857-1867, 1991.
33. 6-alkylguanine-DNA alkyltransferase gene ogt reduces the toxicity of alkylnitrosoureas. Br. J. Cancer, 67: 1196-1202, 1993.
34. Harm W. Biological Effects of Ultraviolet Radiation. Cambridge, United Kingdom: Cambridge University Press, 1980.
35. Clark, A. S., Deans, B., Stevens, M. F. G., Tisdale, M. J., Wheelhouse, R. T., Denny, B. J., and Hartlet, J. A. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J. Med. Chem., 38: 1493-1504, 1995.
36. Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., and Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.
37. Barnes, D. E., Lindhal, T., and Sedgwick, B. DNA repair. Curr. Opin. Cell Biol., 5: 424-433, 1993.
38. Karran, P., and Bignami, M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res., 20: 2933-2940, 1992.
39. 6-methylguanineithymine mispairs in DNA by extracts of human cells. Biochemistry, 31: 7998-8009, 1992.
40. de Wind, N., Dekker, M., Berns, A., Radman, M., and te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination and predisposition to cancer. Cell, 82: 321-330, 1995.
41. Samson, L., Derfler, B., Boosalis, M., and Call, K. Cloning and characterization of a 3-methyladenine DNA glycosylase cDNA from human cells whose gene maps to chromosome 16. Proc. Natl. Acad. Sci. USA, 88: 9127-9131, 1991.
42. Chen, J., Derfler, B., and Samson, L. Saccharomyces cerevisiae 3-methyladenine DNA glycosylase has homology to the Alk A glycosylase of E. coli and is induced in response to DNA alkylation damage. EMBO J., 9: 4569-4575, 1990.
43. Sancar, A., and Sancar, G. B. DNA repair enzymes. Annu. Rev. Biochem.. 57: 29-67, 1988.
44. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., 54: 4313-4320, 1994.
45. Kelley, S. L., Basu, A., Teicher, B. A., Havker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionine confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
46. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
47. Hartwell, L. H., and Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events Science (Washington DC), 246: 629-633, 1989.
48. 1-(2′-deoxyguanosyl)]ethane in DNA reacted with 1-(2-chloroethyl)-l-nitrosourea. Chem. Res. Toxicol., 6: 434-438, 1993.
49. Ludlum, D. B DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat. Res., 233: 117-126, 1990.
50. McCormick, J. E., and McElhinney, R. S. Nitrosoureas from chemist to physician: classification and recent approaches to drug design. Eur. J. Cancer, 26: 207-221, 1990.
51. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol. (NY), 23: 112-116, 1995.